Jump to content

Clostridioides difficile toxin A

From Wikipedia, the free encyclopedia
Clostridioides difficile toxin A
Identifiers
OrganismClostridioides difficile
SymboltoxA
Alt. symbolstcdA
Entrez4914076
RefSeq (Prot)YP_001087137.1
UniProtP16154
Other data
EC number2.4.1.-
Chromosomegenome: 0.79 - 0.81 Mb
Search for
StructuresSwiss-model
DomainsInterPro
SEM of Clostridioides difficile bacteria
PaLoc Reference: Clostridioides difficile strain 630, DSM 27543, genome GenBank accession number AM180355 Positions 770.154 to 789.973 bp, total locus size 19.8 kb.

Clostridioides difficile toxin A (TcdA) is a toxin produced by the bacteria Clostridioides difficile, formerly known as Clostridium difficile.[1] It is similar to Clostridium difficile Toxin B. The toxins are the main virulence factors produced by the gram positive, anaerobic,[2] Clostridioides difficile bacteria. The toxins function by damaging the intestinal mucosa and cause the symptoms of C. difficile infection, including pseudomembranous colitis.

TcdA is one of the largest bacterial toxins known. With a molecular mass of 308 kDa, it is usually described as a potent enterotoxin,[3] but it also has some activity as a cytotoxin.[4] The toxin acts by modifying host cell GTPase proteins by glucosylation, leading to changes in cellular activities. Risk factors for C. difficile infection include antibiotic treatment, which can disrupt normal intestinal microbiota and lead to colonization of C. difficile bacteria.[5]

tcdA gene

[edit]

The gene contains an open reading frame (ORF) of 8,133 nucleotides, coding for 2,710 amino acids. TcdA and TcdB share 63% homology in their amino acid sequences.[6] These genes are expressed during late log phase and stationary phase in response to environmental factors. Environmental stresses such as antibiotics and catabolite repression can influence toxin expression.[7]

Pathogenicity locus

[edit]

The tcdA and tcdB genes are situated on the Clostridioides difficile chromosome in a 19.6-kb pathogenicity locus (PaLoc) found only in toxigenic strains of C. difficile. Non toxigenic strains contain a 127 base pair fragment replacing the PaLoc.[8] This locus also contains three other accessory genes tcdC, tcdR, and tcdE.[9] TcdC expression is high during early exponential phase and declines as growth moves into stationary phase, consistent with increases in tcdA and tcdB expression. Accordingly, expression patterns have indicated tcdC as a possible negative regulator of toxin production. tcdR may serve as a positive regulator of toxin production.[7] tcdE has been speculated to facilitate release of TcdA and TcdB through lytic activity on the bacterial cell membrane. Due to its homology with other proteins of similar function, as well as the location of the gene between tcdA and tcdB, tcdE is predicted to function as the lytic protein that facilitates release since TcdA and TcdB lack a signal peptide for secretion.[8]

Structure

[edit]

The protein contains three domains. The amino N-terminal domain contains the active site, responsible for the glucosylating activity of the toxin. Both TcdA and TcdB use this highly conserved N-terminal region (74% homology between both toxins) to alter identical substrates.[7]

The carboxy C-terminal domain contains repeating units that are responsible for receptor binding on target cell surfaces. These short homologous repeating units have been termed combined repetitive oligopeptide (CROPs).[7][10] A recent study demonstrates that the CROPs determine the potency of TcdA through interactions with structures on the cell surface.[11] These CROP regions range from 21-50 residues and play a role in receptor binding.[7] This C-terminal repetitive region is designated as the immuno-dominant region since ligand binding can be blocked by monoclonal antibodies specific to this region.[12][13] This region contains the most hydrophilic portion of the molecule.[10]

A centrally located hydrophobic domain containing a cluster of 172 highly conserved hydrophobic amino acids is thought to be important for translocation of the enzymatic portion of the protein.[5][6]

Mechanism of action

[edit]

TcdA must be internalized into the host cell via endocytosis in order to access the cytosol. Receptor binding is the first step required for entry into the cell via endocytosis in an acidic endosome.[6] Low pH in the endosome induces structural changes such as exposure of the hydrophobic domains that are crucial for TcdA function.[7][14]

The N-terminal domain of TcdA functions to catalyze a glucotransferase reaction, which transfers a glucose molecule from UDP-Glucose and covalently attaches it to conserved amino acids in target molecules.[6] Therefore, TcdA catalyzes glucosylation and the subsequent irreversible inactivation of target molecules in the Ras family of small GTPases.[9] These target molecules include RhoA, Rac, and Cdc42, which are regulatory proteins of the eukaryotic actin cytoskeleton and modulators of many various cell signaling pathways.[7]

Intracellular targets

[edit]

TcdA primarily targets Rho, Rac, and Cdc42. These molecules are important regulators of cell signaling. Small GTPases such as Rho, Rac, and Cdc42 regulate their activity by alternating between an active GTP-bound state, and an inactive GDP-bound state.[7] Guanine exchange factors (GEFs) regulate the exchange of GTP and GDP.[15]

TcdA glucosylates RhoA by transferring a glucose molecule from UDP-glucose, a nucleotide sugar, to Thr-37 of the RhoA GTPase. In Rac and Cdc42, the sugar moiety is transferred to the Thr-35. The glucosylation prevents proper binding of GTP and blocks activation.[7] TcdA acts preferentially on the GDP-bound form of the GTPase proteins since this configuration exposes the threonine residue that is glucosylated by the toxin.[5]

RhoA regulates the actin cytoskeleton and forms stress fibers and focal adhesions.[16] When RhoA is inactivated via TcdA, its interaction with downstream effectors is inhibited. This leads to changes in the actin cytoskeleton that increase permeability of the intestinal epithelium. Rac and Cdc42 are involved in filopodium formation crucial for movement and cell migration. Overall, Rho, Rac, and Cdc42 all regulate processes in cells that are dependent on actin polymerization. Many of the physiologic effects that cells experience after exposure to TcdA can be linked to disregulation of actin polymerization and cellular pathways controlled by TcdA targets.[7]

Physiologic effects

[edit]

Cell morphology

[edit]

Exposure to TcdA leads to immediate changes in cell morphology, including loss of structural integrity due to a decrease in filamentous actin (F-actin), and an increase in globular actin.[17] Disorganization of actin filaments and the cytoskeleton leads to increased permeability of tight junctions resulting in severe epithelial cell damage and fluid secretion.[18][19] Fluid accumulation and secretion are secondary to mucosal damage that occurs after exposure to TcdA. Distinct changes in the microfilament system lead to cell rounding and cell death.[17] These changes result from the inactivation of Rho proteins, which play an important role in regulating tight junctions.[7][20]

Apoptosis

[edit]

Apoptosis is the most likely mechanism accounting for death of cells exposed to TcdA. Rho inactivation can activate caspase-3 and caspase-9; two key components of the apoptotic pathway. TcdA has been linked to mitochondrial membrane disruption and release of cytochrome C through caspase activation and Rho inactivation, further suggesting that TcdA is capable of inducing apoptosis.[21][22]

Clinical significance

[edit]

Clostridioides difficile associated diarrhea (CDAD)

[edit]

Animal models have shown TcdA includes diarrhea, neutrophil infiltration, inflammation of intestinal mucosa, and necrosis of epithelial cells. This toxin is considered the main cause of CDAD.[18] TcdA damages intestinal villous tips, which disrupts the brush border membrane, leading to cell erosion and fluid leakage from the damaged area. This damage and associated fluid response causes the diarrhea associated with Clostridioides difficile infection.[17]

Pseudomembranous colitis

[edit]

TcdA can induce the physiological changes that occur in C. difficile related pseudomembranous colitis (PMC), a severe ulceration of the colon. Toxin damage to the colonic mucosa promotes accumulations of fibrin, mucin, and dead cells to form a layer of debris in the colon (pseudomembrane), causing an inflammatory response.[5] TcdA damage causes increased epithelial permeability, cytokine and chemokine production, neutrophil infiltration, production of reactive oxygen species (ROS), mast cell activation, and direct damage to the intestinal mucosa.[23] All can be attributed to TcdA induced inactivation of Rho GTPase proteins.[20] Loss of tight junctions can provide entry for neutrophils into the intestines, leading to neutrophil accumulation; a hallmark of PMC. TcdA induced cytokine production of IL-8 and other inflammatory mediators contributes to the stages of inflammation seen in PMC. Infiltration by neutrophils, macrophages, and mast cells in response to TcdA damage increases the inflammatory response through production and release of other mediators such as tumor necrosis factor alpha, IL-1, IL-6, and other monokines. These mediators cause additional damage to intestinal mucosa and further increase the inflammatory response, influencing PMC persistence.[24] If extensive damage to the intestinal wall occurs, bacteria can enter the bloodstream and cause septic shock and death.[5]

Toxin detection and diagnosis

[edit]

TcdA and TcdB are present in supernatant fluids of C. difficile cultures and can be purified from filtrates. Both toxins are consistently detected in fecal samples from humans and animals[25] and are now used as markers to diagnose C. difficile infection.[7] Over 90% of patients infected with C. difficile were found to have cytotoxic activity in their stool. Glucosylation of Rho GTPases inactivates the GTPase proteins, leading to collapse of the cytoskeleton, resulting in cell rounding. A tissue culture assay has been developed to detect C. difficile toxins in stool samples.[17] A cell rounding assay (cytotoxicity assay) has been developed to diagnose C. difficile infection.[11] Enzyme-linked immunosorbent assays (ELISAs) have been used to detect TcdA and TcdB with specific antibodies. When used with an ELISA, the cytotoxicity assay is the "gold standard" when used on Vero cells for C. difficile diagnosis.[11]

Importance of TcdA and TcdB in C. difficile infection

[edit]

Since the 1980s and early 1990s, the roles of TcdA and TcdB in C. difficile infection have been much debated. Previous reports with purified toxins indicated that TcdA alone was enough to cause symptoms of infection and TcdB was unable to do so unless combined with TcdA.[7] A more recent experiment indicated that TcdB was, in fact, essential for virulence.[26] Earlier research established TcdA strictly as an enterotoxin, and TcdB as a cytotoxin, but later both toxins were found to have the same mechanism of action.[6] To fully investigate the role of both toxins in pathogenesis of C. difficile infection, a gene knockout system in a hamster infection model was developed. By permanently knocking out tcdA, tcdB, or both (double knockout), it was shown that C. difficile producing one or both toxins was capable of cytotoxic activity, and this activity translated directly to virulence in vivo. It was also found that a double tcdAtcdB knockout was completely attenuated in virulence. Overall, this research has demonstrated the importance of both TcdA and TcdB in C. difficile infection, showing that either toxin is capable of cytotoxicity.[9]

See also

[edit]

References

[edit]
  1. ^ Planche T, Aghaizu A, Holliman R, Riley P, Poloniecki J, Breathnach A, Krishna S (December 2008). "Diagnosis of Clostridium difficile infection by toxin detection kits: a systematic review". The Lancet Infectious Diseases. 8 (12): 777–84. doi:10.1016/S1473-3099(08)70233-0. PMID 18977696.
  2. ^ Edwards AN, Suárez JM, McBride SM (September 2013). "Culturing and maintaining Clostridium difficile in an anaerobic environment". Journal of Visualized Experiments (79): e50787. doi:10.3791/50787. PMC 3871928. PMID 24084491.
  3. ^ Peterson LR, Holter JJ, Shanholtzer CJ, Garrett CR, Gerding DN (August 1986). "Detection of Clostridium difficile toxins A (enterotoxin) and B (cytotoxin) in clinical specimens. Evaluation of a latex agglutination test". American Journal of Clinical Pathology. 86 (2): 208–11. doi:10.1093/ajcp/86.2.208. PMID 3739972.
  4. ^ Tucker KD, Carrig PE, Wilkins TD (May 1990). "Toxin A of Clostridium difficile is a potent cytotoxin". Journal of Clinical Microbiology. 28 (5): 869–71. doi:10.1128/JCM.28.5.869-871.1990. PMC 267826. PMID 2112562.
  5. ^ a b c d e Winkler ME, Wilson BJ, Salyers AA, Whitt DD (2010). Bacterial Pathogenesis: A Molecular Approach. Metals Park, Ohio: ASM. ISBN 978-1-55581-418-2.
  6. ^ a b c d e Chaves-Olarte E, Weidmann M, Eichel-Streiber C, Thelestam M (October 1997). "Toxins A and B from Clostridium difficile differ with respect to enzymatic potencies, cellular substrate specificities, and surface binding to cultured cells". Journal of Clinical Investigation. 100 (7): 1734–41. doi:10.1172/JCI119698. PMC 508356. PMID 9312171.
  7. ^ a b c d e f g h i j k l m Voth DE, Ballard JD (April 2005). "Clostridium difficile toxins: mechanism of action and role in disease". Clinical Microbiology Reviews. 18 (2): 247–63. doi:10.1128/CMR.18.2.247-263.2005. PMC 1082799. PMID 15831824.
  8. ^ a b Tan KS, Wee BY, Song KP (July 2001). "Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile". J. Med. Microbiol. 50 (7): 613–9. doi:10.1099/0022-1317-50-7-613. PMID 11444771.
  9. ^ a b c Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP (October 2010). "The role of toxin A and toxin B in Clostridium difficile infection". Nature. 467 (7316): 711–3. Bibcode:2010Natur.467..711K. doi:10.1038/nature09397. hdl:10044/1/15560. PMID 20844489. S2CID 4417414.
  10. ^ a b Dove CH, Wang SZ, Price SB, Phelps CJ, Lyerly DM, Wilkins TD, Johnson JL (February 1990). "Molecular characterization of the Clostridium difficile toxin A gene". Infection and Immunity. 58 (2): 480–8. doi:10.1128/IAI.58.2.480-488.1990. PMC 258482. PMID 2105276.
  11. ^ a b c Olling A, Goy S, Hoffmann F, Tatge H, Just I, Gerhard R (2011). "The repetitive oligopeptide sequences modulate cytopathic potency but are not crucial for cellular uptake of Clostridium difficile toxin A". PLOS ONE. 6 (3): e17623. Bibcode:2011PLoSO...617623O. doi:10.1371/journal.pone.0017623. PMC 3060812. PMID 21445253.
  12. ^ Sullivan NM, Pellett S, Wilkins TD (March 1982). "Purification and characterization of toxins A and B of Clostridium difficile". Infection and Immunity. 35 (3): 1032–40. doi:10.1128/IAI.35.3.1032-1040.1982. PMC 351151. PMID 7068210.
  13. ^ von Eichel-Streiber C, Laufenberg-Feldmann R, Sartingen S, Schulze J, Sauerborn M (May 1992). "Comparative sequence analysis of the Clostridium difficile toxins A and B". Molecular Genetics and Genomics. 233 (1–2): 260–8. doi:10.1007/bf00587587. PMID 1603068. S2CID 7052419.
  14. ^ Florin I, Thelestam M (December 1983). "Internalization of Clostridium difficile cytotoxin into cultured human lung fibroblasts". Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 763 (4): 383–92. doi:10.1016/0167-4889(83)90100-3. PMID 6652117.
  15. ^ Zhou K, Wang Y, Gorski JL, Nomura N, Collard J, Bokoch GM (July 1998). "Guanine nucleotide exchange factors regulate specificity of downstream signaling from Rac and Cdc42". Journal of Biological Chemistry. 273 (27): 16782–6. doi:10.1074/jbc.273.27.16782. PMID 9642235.
  16. ^ Just I, Selzer J, von Eichel-Streiber C, Aktories K (March 1995). "The low molecular mass GTP-binding protein Rho is affected by toxin A from Clostridium difficile". Journal of Clinical Investigation. 95 (3): 1026–31. doi:10.1172/JCI117747. PMC 441436. PMID 7883950.
  17. ^ a b c d Lyerly DM, Krivan HC, Wilkins TD (January 1988). "Clostridium difficile: its disease and toxins". Clinical Microbiology Reviews. 1 (1): 1–18. doi:10.1128/cmr.1.1.1. PMC 358025. PMID 3144429.
  18. ^ a b Warny M, Vaerman JP, Avesani V, Delmée M (February 1994). "Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection". Infection and Immunity. 62 (2): 384–9. doi:10.1128/IAI.62.2.384-389.1994. PMC 186119. PMID 8300199.
  19. ^ Hecht G, Pothoulakis C, LaMont JT, Madara JL (November 1988). "Clostridium difficile toxin A perturbs cytoskeletal structure and tight junction permeability of cultured human intestinal epithelial monolayers". Journal of Clinical Investigation. 82 (5): 1516–24. doi:10.1172/JCI113760. PMC 442717. PMID 3141478.
  20. ^ a b Nusrat A, Giry M, Turner JR, Colgan SP, Parkos CA, Carnes D, Lemichez E, Boquet P, Madara JL (November 1995). "Rho protein regulates tight junctions and perijunctional actin organization in polarized epithelia". Proceedings of the National Academy of Sciences of the United States of America. 92 (23): 10629–33. Bibcode:1995PNAS...9210629N. doi:10.1073/pnas.92.23.10629. PMC 40665. PMID 7479854.
  21. ^ Hippenstiel S, Schmeck B, N'Guessan PD, Seybold J, Krüll M, Preissner K, Eichel-Streiber CV, Suttorp N (October 2002). "Rho protein inactivation induced apoptosis of cultured human endothelial cells". American Journal of Physiology. Lung Cellular and Molecular Physiology. 283 (4): L830–8. doi:10.1152/ajplung.00467.2001. PMID 12225960. S2CID 7033902.
  22. ^ Brito GA, Fujji J, Carneiro-Filho BA, Lima AA, Obrig T, Guerrant RL (November 2002). "Mechanism of Clostridium difficile toxin A-induced apoptosis in T84 cells". The Journal of Infectious Diseases. 186 (10): 1438–47. doi:10.1086/344729. PMID 12404159.
  23. ^ Kelly CP, Becker S, Linevsky JK, Joshi MA, O'Keane JC, Dickey BF, LaMont JT, Pothoulakis C (March 1994). "Neutrophil recruitment in Clostridium difficile toxin A enteritis in the rabbit". Journal of Clinical Investigation. 93 (3): 1257–65. doi:10.1172/JCI117080. PMC 294078. PMID 7907603.
  24. ^ Flegel WA, Müller F, Däubener W, Fischer HG, Hadding U, Northoff H (October 1991). "Cytokine response by human monocytes to Clostridium difficile toxin A and toxin B". Infection and Immunity. 59 (10): 3659–66. doi:10.1128/IAI.59.10.3659-3666.1991. PMC 258935. PMID 1910012.
  25. ^ Lima AA, Lyerly DM, Wilkins TD, Innes DJ, Guerrant RL (March 1988). "Effects of Clostridium difficile toxins A and B in rabbit small and large intestine in vivo and on cultured cells in vitro". Infection and Immunity. 56 (3): 582–8. doi:10.1128/IAI.56.3.582-588.1988. PMC 259330. PMID 3343050.
  26. ^ Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI (April 2009). "Toxin B is essential for virulence of Clostridium difficile". Nature. 458 (7242): 1176–9. Bibcode:2009Natur.458.1176L. doi:10.1038/nature07822. PMC 2679968. PMID 19252482.
Retrieved from "http://en.wiki.x.io/w/index.php?title=Clostridioides_difficile_toxin_A&oldid=1226159044"